1. Home
  2. GERN vs NAVI Comparison

GERN vs NAVI Comparison

Compare GERN & NAVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.50

Market Cap

808.3M

Sector

Health Care

ML Signal

HOLD

Logo Navient Corporation

NAVI

Navient Corporation

HOLD

Current Price

$8.36

Market Cap

760.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
GERN
NAVI
Founded
1990
1973
Country
United States
United States
Employees
258
670
Industry
Biotechnology: Pharmaceutical Preparations
Investment Bankers/Brokers/Service
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
808.3M
760.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GERN
NAVI
Price
$1.50
$8.36
Analyst Decision
Hold
Sell
Analyst Count
3
6
Target Price
$2.17
$10.00
AVG Volume (30 Days)
14.8M
1.1M
Earning Date
05-06-2026
04-29-2026
Dividend Yield
N/A
6.73%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$26.91
$76.23
Revenue Next Year
$43.75
$15.73
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.04
$7.33
52 Week High
$2.01
$14.49

Technical Indicators

Market Signals
Indicator
GERN
NAVI
Relative Strength Index (RSI) 65.05 51.01
Support Level $1.44 $7.83
Resistance Level $1.72 $8.40
Average True Range (ATR) 0.09 0.30
MACD 0.03 -0.01
Stochastic Oscillator 68.06 46.81

Price Performance

Historical Comparison
GERN
NAVI

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

About NAVI Navient Corporation

Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in two segments: Federal Education Loans, and Consumer Lending. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.

Share on Social Networks: